1352550-38-9

Basic information

• Product Name: (2E,4E)-2-cyano-N-cyclopropyl-5-[4-(dimethylamino)-phenyl]penta-2,4-dienamide
• Synonyms: (2E,4E)-2-cyano-N-cyclopropyl-5-[4-(dimethylamino)-phenyl]penta-2,4-dienamide
• CAS NO: 1352550-38-9
• Molecular Weight: 281.357
• Mol File: 1352550-38-9.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (2E,4E)-2-cyano-N-cyclopropyl-5-[4-(dimethylamino)-phenyl]penta-2,4-dienamide(CAS DataBase Reference)
• NIST Chemistry Reference: (2E,4E)-2-cyano-N-cyclopropyl-5-[4-(dimethylamino)-phenyl]penta-2,4-dienamide(1352550-38-9)
• EPA Substance Registry System: (2E,4E)-2-cyano-N-cyclopropyl-5-[4-(dimethylamino)-phenyl]penta-2,4-dienamide(1352550-38-9)

Safety Data

• Hazardous Substances Data: 1352550-38-9(Hazardous Substances Data)

Upstream product

• 20432-35-3 3-(4-dimethylamino-phenyl)-propenal 
• 15029-37-5 2-cyano-N-cyclopropylacetamide 

Downstream Products

• 1352550-43-6 (E)-2-cyano-N-cyclopropyl-5-[4-(dimethylamino)-phenyl]pent-4-enamide 

Relevant articles and documents

Arylcyanoacrylamides as inhibitors of the Dengue and West Nile virus proteases

The 3-aryl-2-cyanoacrylamide scaffold was designed as core pharmacophore for inhibitors of the Dengue and West Nile virus serine proteases (NS2B-NS3). A total of 86 analogs was prepared to study the structure-activity relationships in detail. Thereby, it turned out that the electron density of the aryl moiety and the central double bond have a crucial influence on the activity of the compounds, whereas the influence of substituents of the amide residue is less relevant. The para-hydroxy substituted analog was found to be the most potent inhibitor in this series with a Ki-value of 35.7 μM at the Dengue and 44.6 μM at the West Nile virus protease. The aprotinin competition assay demonstrates a direct interaction of the inhibitor molecule with active centre of the Dengue virus protease. The target selectivity was studied in a counterscreen with thrombin and found to be 2.8:1 in favor of DEN protease and 2.3:1 in favor of WNV protease, respectively.